In the phase 3 OptiTROP-Lung06 study, which was run by Kelun in 455 Chinese patients, sac-TMT reduced the risk of disease ...
VOLGA was conducted in patients with MIBC ineligible or unwilling to take platinum-based chemotherapy, who received PD-L1 inhibitor Imfinzi (durvalumab) before and after surgery to remove the tumour, ...
Nubeqa is a key growth product for Bayer, with sales up around 60% to €1.63 billion in the first half of this year from its ...
The full look at the results of the DeLLphi-305 study of Imdelltra (tarlatamab) and Imfinzi (durvalumab) as first-line maintenance therapy for extensive-stage SCLC (ES-SCLC) whose disease had not ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results